AR121839A1 - ANTI-FLT3 ANTIBODIES AND COMPOSITIONS - Google Patents

ANTI-FLT3 ANTIBODIES AND COMPOSITIONS

Info

Publication number
AR121839A1
AR121839A1 ARP210100982A ARP210100982A AR121839A1 AR 121839 A1 AR121839 A1 AR 121839A1 AR P210100982 A ARP210100982 A AR P210100982A AR P210100982 A ARP210100982 A AR P210100982A AR 121839 A1 AR121839 A1 AR 121839A1
Authority
AR
Argentina
Prior art keywords
compositions
flt3 antibodies
flt3
antibodies
patient
Prior art date
Application number
ARP210100982A
Other languages
Spanish (es)
Inventor
Trine Lindsted
Maria Carlsen Melander
Matteo Riva
Mikkel Wandahl Pedersen
Randi Westh Hansen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of AR121839A1 publication Critical patent/AR121839A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Esta invención se refiere a anticuerpos anti-FLT3 y a métodos de uso de los mismos para potenciar la inmunidad en un paciente que lo necesita y para tratar el cáncer.This invention relates to anti-FLT3 antibodies and methods of using them to enhance immunity in a patient in need thereof and to treat cancer.

ARP210100982A 2021-04-14 2021-04-14 ANTI-FLT3 ANTIBODIES AND COMPOSITIONS AR121839A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163009578P 2021-04-14 2021-04-14

Publications (1)

Publication Number Publication Date
AR121839A1 true AR121839A1 (en) 2022-07-13

Family

ID=83218579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100982A AR121839A1 (en) 2021-04-14 2021-04-14 ANTI-FLT3 ANTIBODIES AND COMPOSITIONS

Country Status (1)

Country Link
AR (1) AR121839A1 (en)

Similar Documents

Publication Publication Date Title
CL2022002833A1 (en) Anti-flt3 antibodies and compositions
CO2021001912A2 (en) Anti-cd112r compositions and methods
CL2016000538A1 (en) Compound comprising the h and klh balloon protein, compositions of a carbohydrate vaccine for the induction of immune responses and uses thereof
CL2019002850A1 (en) Combination therapies targeting pd-1, tim-3, and lag-3.
CO2020005887A2 (en) Polycyclic compounds as shp2 allosteric inhibitors
CO2020014009A2 (en) Mcl-1 inhibitors
CO2019004003A2 (en) Anti-lag-3 antibodies and compositions
CL2019001874A1 (en) Context-permissive isoform-specific tgfß1 inhibitors and their use.
CL2017003261A1 (en) Factor xi antibodies and methods of use
BR112019005908A2 (en) use of anti-pd-1 antibody and vegfr inhibitor combination in cancer drug preparation
ECSP22083269A (en) HUMAN MONOCLONAL ANTIBODIES DIRECTED AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
CO2019013669A2 (en) Anti-garp-tgf-β antibodies
CL2020003249A1 (en) Gremlin-1 antagonist for the prevention and treatment of cancer
CL2021001814A1 (en) Acute treatment and rapid treatment of headache using anti-cgrp antibodies.
ECSP21052193A (en) TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
CO2023006684A2 (en) Antibodies against sars-cov-2 and their uses
CR20180521A (en) INHIBITORS OF THE ZESTE 2 HOMOLOGIST POTENTIATOR
CO2020014599A2 (en) Methods to treat cancer
CL2023003562A1 (en) Anti-nkg2a antibodies and compositions
CO2020006907A2 (en) Antimicrobial peptides and methods of using them
CL2023000741A1 (en) Anti-nectin-4 antibody, conjugate that includes it and application thereof.
CO2023008643A2 (en) Anti-hla-g antibodies and their use
CL2023000892A1 (en) Therapeutic compositions and methods for the treatment of hepatitis b (divisional).
CL2023001052A1 (en) Compositions and methods for treatment of thyroid eye disease